No Data
No Data
Express News | Ensysce Biosciences Treats First Group Of Subjects In PF614-MPAR-102 Study
Shareholders Will Likely Find Ensysce Biosciences, Inc.'s (NASDAQ:ENSC) CEO Compensation Acceptable
Express News | Ensysce Biosciences Shares Are Trading Higher After the Company Reported Better-than-expected Q3 Financial Results
Ensysce Biosciences GAAP EPS of $0.07 Beats by $0.24
10-Q: Q3 2024 Earnings Report
8-K: Ensysce Biosciences Reports Third Quarter 2024 Financial Results
No Data
No Data